Skip to main content
    A

    Avita Medical Ltd (RCEL)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $15.22
    -0.41 (-2.62%)

    Market Cap: $491.10M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Avita Medical Ltd (RCEL) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Avita Medical (RCEL) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Avita Medical reported EPS of -$0.20, above the -$0.29 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(14/28)
    Avg Surprise
    -36.22%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.20
    Range-$0.22 - -$0.18
    6 analysts
    Revenue Consensus
    $26.21M
    Range$24.40M - $27.72M
    5 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.26
    Range-$0.31 - -$0.22
    2 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.26+0.2%
    60d ago-$0.26-0.6%
    30d ago-$0.26-0.6%
    7d ago-$0.26+0.4%
    Current-$0.26
    Revenue Consensus
    $36.20M
    Range$35.21M - $38.51M
    4 analysts

    Next Report

    RCEL has an expected report date of Feb 10, 2027.

    RCEL Earnings Call

    The latest RCEL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 28 quarters below that had an estimate, RCEL beat 14 and missed 14. Revenue for the quarter ended Sep 30, 2026 was $26.11M, up 53.0% from $17.06M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.20-$0.29-$0.36 - -$0.23+31.03%BeatN/A44 up, 0 downNov 5, 2026$26.11M
    Jun 30, 2026-$0.25-$0.39-$0.46 - -$0.31+35.90%BeatN/A4N/AAug 6, 2026$21.70M
    Mar 31, 2026-$0.48-$0.38-$0.50 - -$0.27-26.32%MissN/A43 up, 0 downMay 14, 2026$19.25M
    Dec 31, 2025-$0.54-$0.55-$0.77 - -$0.36+1.82%BeatN/A62 up, 1 downFeb 12, 2026$17.62M
    Sep 30, 2025-$0.71-$0.45-$0.66 - -$0.17-57.78%MissN/A60 up, 5 downNov 6, 2025$17.06M
    Jun 30, 2025-$0.38-$0.26-$0.48 - -$0.25-46.15%MissN/A51 up, 0 downAug 7, 2025$18.42M
    Mar 31, 2025-$0.83-$0.51-$0.68 - $0.02-62.75%MissN/A61 up, 1 downMay 8, 2025$18.51M
    Dec 31, 2024-$0.70-$0.74-$0.98 - -$0.30+5.97%BeatN/A70 up, 3 downFeb 13, 2025$18.41M
    Sep 30, 2024-$0.62-$0.44-$0.50 - -$0.35-40.91%MissN/A60 up, 0 downNov 7, 2024$19.55M
    Jun 30, 2024-$0.91-$0.76N/A-19.74%MissN/A50 up, 0 downAug 8, 2024$15.20M
    Mar 31, 2024-$1.10-$0.73-$0.73 - -$0.26-50.68%MissN/A50 up, 0 downMay 13, 2024$11.10M
    Dec 31, 2023-$0.43-$0.57N/A+24.56%BeatN/A52 up, 0 downFeb 22, 2024$14.20M
    Sep 30, 2023-$0.53-$0.68N/A+22.06%BeatN/A51 up, 0 downNov 9, 2023$13.64M
    Jun 30, 2023-$0.63-$0.46N/A-36.96%MissN/A50 up, 0 downAug 10, 2023$11.75M
    Mar 31, 2023-$0.55-$0.36N/A-52.78%MissN/A40 up, 0 downMay 11, 2023$10.55M
    Dec 31, 2022-$0.31-$0.41N/A+24.39%BeatN/A40 up, 0 downFeb 23, 2023$9.46M
    Sep 30, 2022-$0.33-$0.51N/A+35.29%BeatN/A40 up, 0 downNov 10, 2022$9.09M
    Jun 30, 2022-$0.35-$0.57N/A+38.60%BeatN/A44 up, 0 downAug 11, 2022$8.34M
    Mar 31, 2022-$0.55-$0.52N/A-5.77%MissN/A30 up, 0 downMay 12, 2022$7.54M
    Dec 31, 2021-$0.34-$0.37N/A+7.76%BeatN/AN/A0 up, 1 downFeb 28, 2022$6.94M
    Sep 30, 2021-$0.24-$0.38N/A+36.84%BeatN/A4N/ANov 8, 2021$7.02M
    Jun 30, 2021-$0.17-$0.29-$0.40 - -$0.20+41.38%BeatN/A4N/AAug 26, 2021$10.30M
    Mar 31, 2021-$0.34-$0.50N/A+32.00%BeatN/A4N/AMay 13, 2021$7.02M
    Dec 31, 2020-$0.34-$0.59N/A+42.37%BeatN/A4N/AFeb 11, 2021$10.30M
    Sep 30, 2020-$0.66-$0.49-$0.57 - -$0.13-34.69%MissN/A4N/ANov 10, 2020$5.06M
    Jun 30, 2020-$0.60-$0.24N/A-150.00%MissN/AN/AN/AAug 27, 2020$3.88M
    Mar 31, 2020-$0.71-$0.09-$0.12 - $0.00-688.89%MissN/A3N/AApr 29, 2020$3.88M
    Dec 31, 2019-$0.07-$0.03N/A-120.67%MissN/AN/AN/AFeb 18, 2020$3.26M
    Sep 30, 2019Not reported-$0.14N/AN/ANot reportedN/AN/AN/AOct 31, 2019$3.25M
    Jun 30, 2019Not reportedN/AN/AN/ANot reportedN/AN/AN/AAug 29, 2019$2.99M
    Mar 31, 2019Not reportedN/AN/AN/ANot reportedN/AN/AN/AMay 21, 2019$2.95M
    Dec 31, 2018Not reportedN/AN/AN/ANot reportedN/AN/AN/AFeb 27, 2019$826559
    Sep 30, 2018Not reportedN/AN/AN/ANot reportedN/AN/AN/AOct 30, 2018$906618
    Jun 30, 2018Not reportedN/AN/AN/ANot reportedN/AN/AN/AAug 30, 2018$354280
    Mar 31, 2018Not reportedN/AN/AN/ANot reportedN/AN/AN/AApr 29, 2018$295791
    Dec 31, 2017Not reportedN/AN/AN/ANot reportedN/AN/AN/AJan 30, 2018$308201
    Last 36 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.46, after -$3.33 the year before. It was -$0.07 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years below with reported EPS.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.46N/A
    Dec 31, 2024-$3.33N/A
    Dec 31, 2023-$2.14N/A
    Dec 31, 2022-$1.54N/A
    Dec 31, 2021-$1.09N/A
    Dec 31, 2020-$2.31N/A
    Dec 31, 2019-$0.07N/A
    Dec 31, 2018Not reportedN/A
    Dec 31, 2017Not reportedN/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,600 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,5716
    2026Q2Jun 30, 20263,3357
    2026Q1Mar 31, 20264,0468
    2025Q4Dec 31, 20253,8917
    2025Q3Sep 30, 20254,7317
    2025Q2Jun 30, 20255,9077
    2025Q1Mar 31, 20254,2647
    2024Q4Dec 31, 20245,8218

    2026Q3 Earnings Call

    Opening remarks

    Ben Atkins Vice President of Investor Relations Thank you, operator. Welcome to AVITA Medical's Third Quarter 2026 Earnings Call. Joining me on today's call are Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer. Today's earnings release and presentation are available on our website at www.avitamedical.com under the Investor Relations section. Before we begin, I would like to remind you that this call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are neither promises nor guarantees and involve known and unknown risks and uncertainties that could cause actual results to differ materially from any expectations expressed or implied by the forward-looking statements. Please review our most recent filings with the SEC for comprehensive descriptions of the risk factors. Any forward-looking statements provided during this call are based on management's expectations as of today. I will now turn the call over to Cary.

    Cary Vance President and Chief Executive Officer Good afternoon in the U.S. and good morning in Australia. As always, we appreciate you making the time to join us on our quarterly update call. Before I discuss the quarter, I want to acknowledge the clinicians caring for patients with serious burn injuries following the devastating fire at the Wainwright Military Base in Alberta, Canada. At their request, we mobilized quickly. We donated about three dozen RECELL units to burn centers in Calgary and Edmonton and sent AVITA staff to train and to support the clinical teams. Within days, the first patient received treatment with RECELL. Serious burn injuries can happen without warning. Responding takes preparation, access to treatment, and people ready to act. I want to thank our team, the clinicians and burn community in Canada, and the American Burn Association for connecting us. RECELL is not commercially available in Canada, and we are grateful to Health Canada for acting quickly to facilitate access. This response brings us back to why we do this work, helping people heal from serious wounds and return to their lives. Let me turn to our third quarter performance. Revenue reached $26.1 million, up 53% year-over-year and 20% from the second quarter. RECELL led that growth, supported by increasing adoption of Cohealyx. We will further discuss our product dynamics in a moment. At the same time, we reduced cash use to approximately $600,000 compared with $3.2 million in Q2. We are growing revenue, but we are also managing expenses and cash diligently. That combination continues to improve the financial position of the company. Based on our performance, we are raising full-year revenue guidance for the second consecutive quarter. We now expect revenue of $92 million-$94 million for the full year, compared with our previous range of $86 million-$89 million.

    Frequently Asked Questions About RCEL

    When is Avita Medical's next earnings date?

    Avita Medical's next earnings report is expected for Feb 10, 2027.

    Did RCEL beat earnings estimates last quarter?

    Yes. Avita Medical reported EPS of -$0.20 for the quarter ended Sep 30, 2026, above the -$0.29 estimate, a 31.03% surprise.

    What EPS do analysts expect from RCEL next quarter?

    The consensus EPS estimate for Avita Medical for the quarter ending Dec 31, 2026 is -$0.20 from 6 analysts, with estimates from -$0.22 to -$0.18.

    How often does RCEL beat earnings estimates?

    Avita Medical beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -14.78%.